Home Sitemap Contact us Accessibility Statement Top of the page
  • Azilect® (rasagiline) Teva

    Azilect®

    (rasagiline)

Prescribing Azilect®

Azilect® (rasagiline) 1mg tablets

Therapeutic indications

Azilect® is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Azilect® is an irreversible monoamine oxidase type B (MAO-B) inhibitor.1

About Azilect®

Azilect® (rasagiline) tablet contains 1mg rasagiline (as mesilate). For a full list of excipients, see Section 6.1. of the Summary of Product Characteristics.

The tablet is white to off-white, round, flat, bevelled tablets, debossed with “GIL” and “1” underneath on one side
and plain on the other side.1


Marketing Authorisation

Teva Pharma GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

Marketing Authorisation Number(s)

EU/1/04/304/001-007

Resources for Azilect®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect
Medicine supporting documentation for Azilect®

1 Azilect® (rasagiline) Summary of Product Characteristics.

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a